Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Kestra Private Wealth Services LLC

Kestra Private Wealth Services LLC lessened its position in Illumina, Inc. (NASDAQ:ILMN) by 37.4% in the 4th quarter, Holdings Channel reports. The fund owned 2,932 shares of the life sciences company’s stock after selling 1,752 shares during the period. Kestra Private Wealth Services LLC’s holdings in Illumina were worth $408,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. abrdn plc lifted its stake in shares of Illumina by 764.9% in the fourth quarter. abrdn plc now owns 339,023 shares of the life sciences company’s stock valued at $47,206,000 after purchasing an additional 299,827 shares during the period. J.P. Morgan Private Wealth Advisors LLC acquired a new stake in shares of Illumina in the third quarter valued at about $29,558,000. International Assets Investment Management LLC lifted its stake in shares of Illumina by 210.5% in the fourth quarter. International Assets Investment Management LLC now owns 48,194 shares of the life sciences company’s stock valued at $6,711,000 after purchasing an additional 32,672 shares during the period. Aquila Investment Management LLC raised its position in Illumina by 150.0% during the fourth quarter. Aquila Investment Management LLC now owns 25,000 shares of the life sciences company’s stock worth $3,481,000 after acquiring an additional 15,000 shares during the last quarter. Finally, Weil Company Inc. raised its position in Illumina by 59.2% during the third quarter. Weil Company Inc. now owns 22,963 shares of the life sciences company’s stock worth $3,152,000 after acquiring an additional 8,539 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Trading Down 5.2 %

NASDAQ ILMN opened at $112.82 on Wednesday. The company’s fifty day simple moving average is $129.13 and its 200-day simple moving average is $126.95. Illumina, Inc. has a 52 week low of $89.00 and a 52 week high of $213.91. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.26. The stock has a market cap of $17.97 billion, a P/E ratio of -13.84 and a beta of 1.20.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, May 2nd. The life sciences company reported $0.09 EPS for the quarter, topping analysts’ consensus estimates of $0.04 by $0.05. The business had revenue of $1.08 billion for the quarter, compared to analysts’ expectations of $1.05 billion. Illumina had a negative net margin of 28.71% and a positive return on equity of 2.31%. The business’s revenue for the quarter was down 1.0% compared to the same quarter last year. During the same period in the previous year, the company posted $0.08 earnings per share. Equities research analysts predict that Illumina, Inc. will post 0.91 EPS for the current fiscal year.

Insider Activity at Illumina

In related news, CEO Jacob Thaysen purchased 7,330 shares of the business’s stock in a transaction that occurred on Thursday, February 22nd. The shares were purchased at an average cost of $135.29 per share, with a total value of $991,675.70. Following the completion of the acquisition, the chief executive officer now directly owns 14,861 shares of the company’s stock, valued at approximately $2,010,544.69. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.17% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities research analysts have recently commented on ILMN shares. Scotiabank lowered their price target on shares of Illumina from $185.00 to $176.00 and set a “sector outperform” rating for the company in a report on Monday. StockNews.com downgraded shares of Illumina from a “buy” rating to a “hold” rating in a report on Friday, May 3rd. Stephens restated an “overweight” rating and issued a $170.00 target price on shares of Illumina in a report on Tuesday. Barclays boosted their target price on shares of Illumina from $85.00 to $100.00 and gave the company an “underweight” rating in a report on Wednesday, April 10th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $253.00 target price on shares of Illumina in a report on Tuesday, April 9th. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $164.65.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.